SRTA - Strata Critical Medical, Inc. Latest News | Finranks

Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?

Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?

Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know

Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know

The consensus price target hints at a 60% upside potential for Strata Critical Medical, Inc. (SRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript

Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript

Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript

Strata Critical Medical Announces Second Quarter 2026 Results

Strata Critical Medical Announces Second Quarter 2026 Results

Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenue Q2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenue Adjusted EBITDA (1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9% Cash flow from operating activities was $5.7 million in Q2 2026; Free Cash Flow (1) was $2.9 million in Q2 2026 Completed bolt-on acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program and Ohio Valley Perfusion Associates during Q2 2026 Signed agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis over the next year NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the second quarter ended June 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

Videos

No Data

There is no data to display

Press releases

Strata Critical Medical Announces Second Quarter 2026 Results

Strata Critical Medical Announces Second Quarter 2026 Results

Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenue Q2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenue Adjusted EBITDA (1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9% Cash flow from operating activities was $5.7 million in Q2 2026; Free Cash Flow (1) was $2.9 million in Q2 2026 Completed bolt-on acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program and Ohio Valley Perfusion Associates during Q2 2026 Signed agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis over the next year NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the second quarter ended June 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.